A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients

Journal of Ovarian Research

Volumn 7, Issue 1, 2014, Pages

  Zhang, Meiying ^a   He, Yifeng ^a   Sun, Xiangjun ^a   Li, Qing ^a   Wang, Wenjing ^a   Zhao, Aimin ^a   Di, Wen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

M1; M2; Ovarian cancer; Prognosis; Tumor associated macrophage

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL DENSITY; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PARAMETERS; KAPLAN MEIER METHOD; M1 TUMOR ASSOCIATED MACROPHAGE; M2 TUMOR ASSOCIATED MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; UNDIFFERENTIATED CARCINOMA; CHEMISTRY; CHI SQUARE DISTRIBUTION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; MACROPHAGE; MORTALITY; MULTIVARIATE ANALYSIS; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; TIME;

TUMOR MARKER;

ADULT; AGED; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893655060     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-7-19     Document Type: Article

References (83)

1. Ovarian cancer: insights into genetics and pathogeny. Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu ID, Histol Histopathol 2012 27 707 719 22473692
2. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Prat J, Virchows Arch 2012 460 237 249 10.1007/s00428-012-1203-5 22322322
3. Ovarian cancer management: the role of imaging and diagnostic challenges. Bharwani N, Reznek RH, Rockall AG, Eur J Radiol 2011 78 41 51 10.1016/j.ejrad.2010.11.039 21392907
4. Surgical management of epithelial ovarian cancer. Salani R, Bristow RE, Clin Obstet Gynecol 2012 55 75 95 10.1097/GRF.0b013e31824b4629 22343231
5. The Biology of the Macrophage. Ross JA, Auger MJ, Origins of the Macrophage Oxford (United Kingdom): Oxford University Press, Burke B, Lewis CE, 2 2002
6. Regulation of monocytes and macrophages cell fate. Gonzalez-Mejia ME, Doseff AI, Front Biosci (Landmark Ed) 2009 14 2413 2431 19273209
7. Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. Opdenakker G, Van Damme J, Cytokine 1992 4 251 258 10.1016/1043-4666(92)90064-X 1515548
8. Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors. Staudt ND, Jo M, Hu J, Bristow JM, Pizzo DP, Gaultier A, VandenBerg SR, Gonias SL, Cancer Res 2013 73 3902 3912 10.1158/0008-5472.CAN- 12-4233 23633492
9. In vitro assay of spontaneous cytotoxicity by human monocytes and macrophages against tumor cells. Mukherji B, J Immunol Methods 1980 37 233 247 10.1016/0022-1759(80)90310-5 7451996
10. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells. Tokunaga N, Murakami T, Endo Y, Nishizaki M, Kagawa S, Tanaka N, Fujiwara T, Clin Cancer Res 2005 11 1312 1318 15709203
11. Sensitivity of human melanoma cells to adherent leukocytes depends on the ratio between them, the activation status of adherent leukocytes and the metastatic potential of tumor cells. Thomas C, Fertil B, Cancer Immunol Immunother 2001 50 181 190 10.1007/s002620100186 11459170
12. Distinct role of macrophages in different tumor microenvironments. Lewis CE, Pollard JW, Cancer Res 2006 66 605 612 10.1158/0008-5472.CAN-05-4005 16423985
13. Expression of arginase by mouse myeloid leukemic cell differentiation in vitro induced with tumor necrosis factor. Kosaka T, Kuwabara M, Endo A, Tamaguchi H, Koide F, J Vet Med Sci 1991 53 53 57 10.1292/jvms.53.53 1830780
14. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M, Hum Immunol 2009 70 325 330 10.1016/j.humimm.2009.02.008 19236898
15. M-1/M-2 macrophages and the Th1/Th2 paradigm. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM, J Immunol 2000 164 6166 6173 10843666
16. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL, J Pathol 2000 190 430 436 10.1002/(SICI)1096-9896(200003)190:4<430::AID- PATH538>3.0.CO;2-6 10699991
17. Multiple roles of chemokine(C-C motif) ligand 2 in promoting prostate cancer growth. Zhang J, Lu Y, Pienta KJ, J Natl Cancer Inst 2010 102 522 528 10.1093/jnci/djq044 20233997
18. IL10, IL11, IL18 are differently expressed in CD14+ TAMs and play different role in regulating the invasion of gastric cancer cells under hypoxia. Shen Z, Seppainen H, Vainionpaa S, Ye Y, Wang S, Cytokine 2012 59 352 357 10.1016/j.cyto.2012.04.033 22595646
19. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Kong LY, Wu AS, Doucette T, Wei J, Priebe W, Fuller GN, Qiao W, Sawaya R, Rao G, Heimberger AB, Clin Cancer Res 2010 16 5722 5733 10.1158/1078-0432.CCR-10-1693 20921210
20. Macrophage polarization:tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, Trends Immunol 2002 23 549 555 10.1016/S1471-4906(02)02302-5 12401408
21. Precursors and pathogenesis of ovarian carcinoma. Lim D, Oliva E, Pathology 2013 45 229 242 10.1097/PAT.0b013e32835f2264 23478230
22. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. McCluggage WG, Pathology 2011 43 420 432 10.1097/PAT.0b013e328348a6e7 21716157
23. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Kurman RJ, Shih IM, Hum Pathol 2011 42 918 931 10.1016/j.humpath.2011.03.003 21683865
24. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Kurman RJ, Shih IM, Am J Surg Pathol 2010 34 433 443 10.1097/PAS.0b013e3181cf3d79 20154587
25. Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. Wong KH, Mang OW, Au KH, Law SC, Hong Kong Med J 2012 18 466 474 23223646
26. Ovarian cancer incidence and mortality in American Indian, Hispanic, and non-Hispanic white women in New Mexico. Schiff M, Becker TM, Smith HO, Gilliland FD, Key CR, Cancer Epidemiol Biomarkers Prev 1996 5 323 327 9162296
27. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY, Nature 2013 495 241 245 10.1038/nature11979 23467088
28. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA, Mod Pathol 2010 23 781 789 10.1038/modpathol.2010. 41 20305618
29. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmgvist R, PloS One 2012 7 47045 10.1371/journal.pone.0047045 23077543
30. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P, Eur Respir J 2009 33 118 126 10.1183/09031936.00065708 19118225
31. Protein expression changes in ovarian cancer during the transition from benign to malignant. Waldemarson S, Krogh M, Alaiya A, Kirik U, Schedvins K, Auer G, Hansson KM, Ossola R, Lee H, Malmstrom J, James P, J Proteome Res 2012 11 2876 2889 10.1021/pr201258q 22471520
32. Classifications of ovarian cancer tissues by proteomic patterns. Zhu Y, Wu R, Sangha N, Yoo C, Cho KR, Shedden KA, Katabuchi H, Lubman DM, Proteomics 2006 6 5846 5856 10.1002/pmic.200600165 17068758
33. Denny L, Hacker NF, Gori J, Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers London: Elsevier 3 2006
34. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, PloS One 2011 6 21121 10.1371/journal.pone.0021121 21754983
35. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. Medrek C, Ponten F, Jirstrom K, Leandersson K, BMC Cancer 2012 12 306 10.1186/1471-2407-12-306 22824040
36. Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas. Dun EC, Hanley K, Wieser F, Bohman S, Yu J, Taylor RN, Int J Gynecol Pathol 2013 32 576 584 10.1097/PGP.0b013e318284e198 24071874
37. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, Beppu T, Baba H, Takeya M, Cancer Sci 2010 101 1913 1919 10.1111/j.1349-7006.2010.01614.x 20545696
38. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular Carcinoma. Kong L-Q, Zhu X-D, Xu H-X, Zhang J-B, Lu L, PloS One 2013 8 59771 10.1371/journal.pone.0059771 23555776
39. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Costa NL, Valadares MC, Souza PP, Mendonça EF, Oliveira JC, Silva TA, Batista AC, Oral Oncol 2013 49 216 223 10.1016/j.oraloncology.2012.09.012 23089461
40. Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: A quid pro quo in pancreatic cancer. Partecke LI, Günther C, Hagemann S, Jacobi C, Merkel M, Sendler M, van Rooijen N, Käding A, Nguyen Trung D, Lorenz E, Diedrich S, Weiss FU, Heidecke CD, von Bernstorff W, Pancreatology 2013 13 508 516 10.1016/j.pan.2013.06.010 24075516
41. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Shigeoka M, Urakawa N, Nakamura T, Nishio M, Watajima T, Kuroda D, Komori T, Kakeji Y, Semba S, Yokozaki H, Cancer Sci 2013 104 1112 1119 10.1111/cas.12188 23648122
42. Tumor associated macrophage (TAM) infiltration in gastric cancer. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Okumura H, Anticancer Res 2003 23 4079 4083 14666722
43. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Qing W, Fang WY, Ye L, Shen LY, Zhang XF, Fei XC, Chen X, Wang WQ, Li XY, Xiao JC, Ning G, Thyroid 2012 22 905 910 10.1089/thy.2011.0452 22870901
44. Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. Kawanaka T, Kubo A, Ikushima H, Sano T, Takegawa Y, J Med Invest 2008 55 78 86 10.2152/jmi.55.78 18319549
45. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy. Ajili F, Kourda N, Darouiche A, Chebil M, Boubaker S, Ultrastruct Pathol 2013 37 56 61 10.3109/01913123.2012.728688 23383616
46. Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Fujii T, Shimada K, Asai O, Tanaka N, Fujimoto K, Hirao K, Konishi N, Pathobiology 2013 80 119 126 10.1159/000342396 23328608
47. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ, PLoS One 2012 7 50946 10.1371/journal.pone.0050946 23284651
48. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. Dong Y, Walsh MD, Cummings MC, Wright RG, Khoo SK, Parsons PG, McGuckin MA, J Pathol 1997 183 311 317 10.1002/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3. 0.CO;2-2 9422987
49. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Tashiro Y, Yonezawa S, Kim YS, Sato E, Hum Pathol 1994 25 364 372 10.1016/0046-8177(94)90144-9 8163269
50. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Inaba T, Sano H, Kawahito Y, Hla T, Akita K, Proc Natl Acad Sci 2003 100 2736 2741 10.1073/pnas.0435410100 12598658
51. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM, Moniaux N, Batra SK, Mod Pathol 2006 19 1386 1394 10.1038/modpathol.3800646 16880776
52. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK, Cancer 2009 115 1395 1403 10.1002/cncr.24152 19195045
53. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Singh AP, Senapati S, Ponnusamy MP, Jain M, Lele SM, Davis JS, Remmenga S, Batra SK, Lancet Oncol 2008 9 1076 1085 10.1016/S1470-2045(08)70277- 8 19012856
54. P53 autoantibodies, cytokine levels and ovarian carcinogenesis. Tsai-Turton M, Santillan A, Lu D, Bristow RE, Chan KC, Shih IM, Roden RB, Gynecol Oncol 2009 114 12 17 10.1016/j.ygyno.2009.03.028 19398128
55. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G, Mantovani A, Clin Dev Immunol 2010 2010 547179 21331365
56. Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. Albarracin CT, Jafri J, Montag AG, Hart J, Kuan SF, Hum Pathol 2000 31 672 677 10.1053/hupa.2000.6799 10872659
57. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Garg K, Leitao MM Jr, Kauff ND, Hansen J, Kosarin K, Shia J, Soslow RA, Am J Surg Pathol 2009 33 925 933 10.1097/PAS.0b013e318197a046 19238076
58. Therapeutic gene modified cell based cancer vaccines. Kozłowska A, Mackiewicz J, Mackiewicz A, Gene 2013 525 200 207 10.1016/j.gene.2013.03.056 23566846
59. Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins. Hodges RR, Dartt DA, Exp Eye Res 2013 117 62 78 23954166
60. Mesothelin-MUC16 binding is a high affinity. N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS, Mol Cancer 2006 5 50 10.1186/1476-4598-5-50 17067392
61. Roles of the gel-forming MUC2 mucin and its O-glycosylation in the protection against colitis and colorectal cancer. Kawashima H, Biol Pharm Bull 2012 35 1637 1641 10.1248/bpb.b12-00412 23037153
62. Increased understanding of the biochemistry and biosynthesis of MUC2 and other gel-forming mucins through the recombinant expression of their protein domains. Bäckström M, Ambort D, Thomsson E, Johansson ME, Hansson GC, Mol Biotechnol 2013 54 250 256 10.1007/s12033-012-9562-3 23359125
63. Gel-forming mucins. Notions from in vitro studies. Perez-Vilar J, Mabolo R, Histol Histopathol 2007 22 455 464 17290356
64. Importance of direct macrophage-tumor cell interaction on progression of human glioma. Komohara Y, Horlad H, Ohnishi K, Fujiwara Y, Bai B, Nakagawa T, Suzu S, Nakamura H, Kuratsu J, Takeya M, Cancer Sci 2012 103 2165 2172 10.1111/cas.12015 22957741
65. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Kostova N, Zlateva S, Ugrinova I, Pasheva E, Mol Cell Biochem 2010 337 251 258 10.1007/s11010-009-0305-0 19876719
66. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Vaksman O, Davidson B, Tropé C, Reich R, Hum Pathol 2013 44 2677 2683 10.1016/j.humpath.2013.07.009 24060004
67. The immunogenicity of tumor cell death. Kepp O, Tesniere A, Zitvogel L, Kroemer G, Curr Opin Oncol 2009 21 71 76 10.1097/CCO.0b013e32831bc375 19125021
68. Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Melichar B, Savary CA, Patenia R, Templin S, Melicharova K, Freedman RS, Int J Gynecol Cancer 2003 13 435 443 10.1046/j.1525-1438.2003. 13331.x 12911719
69. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b + macrophages in advanced ovarian cancer. Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, Cha HJ, Schwendener RA, Jang KY, Kim KS, Alitalo K, Koh GY, Cancer Res 2008 68 1100 1109 10.1158/0008-5472.CAN- 07-2572 18281485
70. Tracking NF-kappaB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee HJ, Yull F, Khabele D, J Ovarian Res 2013 6 63 10.1186/1757-2215-6-63 24020521
71. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Zaki MA, Wada N, Ikeda J, Shibayama H, Hashimoto K, Yamagami T, Tatsumi Y, Tsukaguchi M, Take H, Tsudo M, Morii E, Aozasa K, Virchows Arch 2011 459 361 366 10.1007/s00428-011-1140-8 21874508
72. Prognostic value of tumor-associated macrophage count in human bladder cancer. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y, Int J Urol 2000 7 263 269 10.1046/j.1442-2042.2000.00190.x 10910229
73. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A, Int J Oncol 2000 17 445 451 10938382
74. Colony stimulating factor 1 promotes progression of mammary tumors to malignancy. Lin EY, Nguyen AV, Russell RG, Pollard JW, J Exp Med 2001 193 727 740 10.1084/jem.193.6.727 11257139
75. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schäfer R, Stanley ER, Abraham D, Cancer Res 2004 64 5378 5384 10.1158/0008-5472.CAN-04- 0961 15289345
76. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R, Clin Cancer Res 2007 13 1472 1479 10.1158/1078-0432.CCR- 06-2073 17332291
77. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. Ma J, Liu L, Che G, Yu N, Dai F, You Z, BMC Cancer 2010 10 112 10.1186/1471-2407-10-112 20338029
78. Cytotoxic activity of human pulmonary alveolar macrophages. Kan-Mitchell J, Hengst JC, Kempf RA, Rothbart RK, Simons SM, Brooker AS, Kortes VL, Mitchell MS, Cancer Res 1985 45 453 458 3965151
79. Effects on in vitro tumor growth of macrophages isolated from human ascitic ovarian tumors. Mantovani A, Peri G, Polentarutti N, Bolis G, Mangioni C, Spreafico F, Int J Cancer 1979 23 157 164 10.1002/ijc.2910230204 761940
80. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N, Br J Cancer 2013 108 914 923 10.1038/bjc.2013.32 23385730
81. M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles. Herwig MC, Bergstrom C, Wells JR, Höller T, Grossniklaus HE, Exp Eye Res 2013 107 52 58 23206928
82. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, Baroni G, Lanciotti M, Serni S, Chiarugi P, Oncogene 2013 Epub ahead of print, doi:10.1038/onc.2013.191
83. Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer. Cui YL, Li HK, Zhou HY, Zhang T, Li Q, Asian Pac J Cancer Prev 2013 14 1003 1007 10.7314/APJCP.2013.14.2.1003 23621176